Xpreza Azacitidine – 100 mg Injection

At a Glance

Generic Name: Azacitidine

Brand Name: Xpreza 100 mg

Strength & Pack Size: 100 mg azacitidine per vial, 1 single-use vial

Dosage Form & Route: Lyophilised powder for subcutaneous injection or intravenous use after reconstitution

Therapeutic Class: Hypomethylating antineoplastic agent (pyrimidine nucleoside analogue)

Primary Indications: Selected myelodysplastic syndromes (MDS), certain AML and chronic myelomonocytic leukaemia (CMML), according to local label

Typical Use in Therapy: Cyclical treatment in specialist haematology units, often as lower-intensity therapy in higher-risk MDS and older AML patients

Mode of Action: Incorporates into RNA/DNA and inhibits DNA methyltransferase, leading to hypomethylation and cytotoxicity in abnormal haematopoietic cells

Key Benefits: Can improve blood counts, delay progression to AML and extend survival in carefully selected patients

Precautions: Requires close monitoring of blood counts, organ function, injection site reactions and infection risk

Storage: Store the vial as per carton instructions, usually refrigerated or below a defined temperature, protected from light until reconstitution

Product Description

Xpreza 100 mg contains azacitidine, a hypomethylating antineoplastic agent used in the treatment of certain myelodysplastic syndromes, selected cases of acute myeloid leukaemia and chronic myelomonocytic leukaemia. Each vial provides 100 mg of azacitidine as a lyophilised powder that must be reconstituted with an appropriate diluent before administration. Xpreza 100 mg azacitidine injection is given in cycles, usually as subcutaneous injections or intravenous infusions in a specialist haematology setting.

For many higher-risk MDS patients and some older adults with AML or CMML, azacitidine offers an important treatment option when intensive induction chemotherapy or transplantation is not appropriate or is being deferred. By targeting abnormal marrow cells and altering gene expression patterns, Xpreza 100 mg azacitidine injection can stabilise disease, improve blood counts, reduce transfusion dependence and delay progression to more aggressive leukaemia in a subset of patients. Treatment is typically long-term and requires patience, as responses may take several cycles to become apparent.

Generic Meds Mart supplies Xpreza 100 mg azacitidine injection in original, sealed oncology packaging from licensed manufacturers and authorised distributors. Vials are shipped in neutral outer cartons that do not mention MDS, AML or azacitidine on the exterior, helping protect patient privacy. Inner packaging retains full information, including brand name, strength, batch number and expiry date, so hospital pharmacies can verify the product before preparing each dose. Pricing is presented in USD, supporting transparent planning for repeated azacitidine cycles that may span many months.

Key Uses

Within the framework of local regulatory approvals and guidelines, Xpreza 100 mg azacitidine injection is used for selected myelodysplastic syndromes, including higher-risk subtypes, and for certain presentations of AML and CMML in adults. Typical candidates include patients with significant cytopenias or higher-risk disease features who may not be suitable for intensive induction chemotherapy. Azacitidine treatment is usually delivered as a 7-day or modified 5–7-day cycle repeated every 28 days, although exact schedules vary by protocol and patient tolerance.

The haematology team will decide whether Xpreza 100 mg azacitidine injection is appropriate based on bone marrow findings, cytogenetics, molecular markers, performance status, comorbidities and patient preferences. Azacitidine may be used as a stand-alone disease-modifying therapy, as a bridge to transplant in selected cases or as a long-term management strategy aimed at improving quality of life and delaying disease progression. It is not a “quick fix” and requires regular clinic visits, laboratory monitoring and supportive care.

How Azacitidine Works in Chemotherapy

Azacitidine, the active ingredient in Xpreza 100 mg injection, is a pyrimidine nucleoside analogue with both hypomethylating and cytotoxic properties. Inside cells, azacitidine is incorporated into RNA and, after conversion to its deoxy form, into DNA. When incorporated into DNA, azacitidine inhibits DNA methyltransferase, an enzyme involved in maintaining normal DNA methylation patterns.

By inhibiting DNA methyltransferase, azacitidine leads to hypomethylation of DNA in rapidly dividing abnormal haematopoietic cells. This can reactivate silenced tumour suppressor genes and alter gene expression profiles in a way that reduces the growth advantage of dysplastic or leukaemic cells. At higher doses, azacitidine also has direct cytotoxic effects, causing damage to abnormal cells that are synthesising DNA.

Through these mechanisms, Xpreza 100 mg azacitidine injection can reduce the burden of abnormal clones in the bone marrow and allow healthier progenitor cells to recover. This may translate into improved blood counts, reduced transfusion needs and delayed transformation to overt leukaemia in some patients. However, the same actions also affect normal dividing cells, which is why careful dose selection and monitoring are essential.

Dosage & Administration

Xpreza 100 mg azacitidine injection must only be prescribed and supervised by haematologists experienced in treating MDS, AML and related disorders. The dose is usually calculated based on body surface area (mg/m²) and adjusted according to response, blood counts and tolerability. After reconstitution, azacitidine can be administered subcutaneously into the abdomen, thigh or upper arm, or given intravenously as an infusion, following the product information and local protocols.

Treatment is typically cyclical, with azacitidine given for several consecutive days followed by a rest period. Patients often receive premedication or supportive antiemetics to reduce nausea and vomiting. Blood counts and biochemistry are checked regularly to guide dose delays or reductions and to decide whether growth factors, transfusions or infection prophylaxis are needed. Xpreza 100 mg azacitidine injection should never be self-prepared or self-administered; all handling and administration are undertaken by trained staff in a clinic or hospital.

Precautions

Before starting Xpreza 100 mg azacitidine injection, the haematology team conducts a thorough review of bone marrow status, blood counts, liver and kidney function, infection history and concomitant medicines. Because azacitidine can cause myelosuppression, patients require ongoing monitoring for neutropenia, thrombocytopenia and anaemia, with timely intervention if counts fall.

Injection site reactions are common with subcutaneous dosing, so patients are advised about rotating injection sites and reporting severe redness, pain or nodules. Nausea, vomiting and diarrhoea are frequent early in treatment, making antiemetics and hydration protocols important. Azacitidine is contraindicated in pregnancy and breastfeeding, and effective contraception is usually recommended during treatment and for a period afterwards. Decisions about continuing, interrupting or stopping Xpreza 100 mg azacitidine injection depend on response, tolerance and evolving clinical status.

Azacitidine Side Effects

Common side effects

Common azacitidine side effects with Xpreza 100 mg injection include low blood counts (neutropenia, thrombocytopenia and anaemia), injection site redness or bruising, nausea, vomiting, diarrhoea or constipation, loss of appetite, fatigue, mild fever, and general weakness. Some patients experience transient kidney or liver test abnormalities, mild headache or injection site pain. These effects are often most noticeable during early cycles and may stabilise or become more manageable as the team refines dosing and supportive care.

Many of these common azacitidine side effects can be addressed with antiemetics, careful hydration, local skin care, growth factor support, transfusions and temporary dose adjustments or delays. Patients are encouraged to keep a symptom diary and bring concerns to clinic visits so that the haematology team can optimise supportive measures.

Serious side effects

Serious azacitidine adverse effects require prompt medical attention. These can include severe or prolonged neutropenia with high risk of infection, sepsis, severe thrombocytopenia with active bleeding, severe gastrointestinal toxicity with dehydration, acute kidney or liver dysfunction, hypersensitivity reactions and, rarely, serious local reactions or tissue damage at injection sites.

Patients should be instructed to contact their treatment centre or emergency services immediately if they develop high fever, chills, shortness of breath, chest pain, uncontrolled vomiting or diarrhoea, black or bloody stools, unusual bleeding or bruising, marked decrease in urine output, confusion or any other alarming symptom. The medical team may need to hold further doses of Xpreza 100 mg azacitidine injection, adjust the regimen or intensify supportive care depending on the severity and suspected cause.

Storage

Xpreza 100 mg azacitidine injection vials should be stored as indicated on the product carton and in the package leaflet, which may include refrigerated storage or a controlled room temperature range. Vials must be kept in the original outer carton to protect from light and should remain out of the reach of children. Reconstituted suspensions or solutions have limited stability and must be prepared and used within the timeframes specified by the manufacturer and local cytotoxic preparation guidelines. Any unused product and materials that have been in contact with azacitidine must be discarded as cytotoxic waste.

Why Buy from Generic Meds Mart

Generic Meds Mart focuses on structured access to essential haematology and oncology medicines such as Xpreza 100 mg azacitidine injection. We source only from licensed manufacturers and authorised distributors that comply with Good Manufacturing Practice and provide full batch traceability. Each vial of Xpreza 100 mg is supplied in sealed original packaging, allowing hospital pharmacies and clinic staff to verify brand, strength, batch number and expiry before preparation.

By listing Xpreza 100 mg azacitidine injection in USD, Generic Meds Mart helps patients and centres plan the cost of repeated treatment cycles. Neutral shipping cartons preserve confidentiality during international delivery, while tracking (where available) allows coordination of shipments with clinic appointments and laboratory monitoring. Our role is to support access and logistics; all decisions about whether, when and how to use azacitidine remain entirely with the treating haematology team.

Order Now

Xpreza 100 mg azacitidine injection is a specialised medicine for MDS, AML and CMML that must never be used without a clear plan from an experienced haematologist. Before arranging supply through Generic Meds Mart, the team should confirm diagnosis, risk category, treatment goals, suitability for azacitidine, proposed dosing schedule and expected duration of therapy. They should also ensure that appropriate monitoring, transfusion support and emergency care pathways are in place.

Once this framework is agreed, the centre or designated purchaser can estimate how many vials of Xpreza 100 mg are needed for the first several cycles. They can then select the corresponding quantity on Generic Meds Mart, add it to the cart and complete secure checkout in USD. Medicines are dispatched in discreet outer packaging with full original labelling inside. Patients and caregivers should never attempt to reconstitute or inject azacitidine themselves unless explicitly trained and authorised by their team, and any new or severe symptoms should be reported promptly for evaluation.

FAQ about Xpreza (Azacitidine)

Q1: What is Xpreza 100 mg used for?
Xpreza 100 mg contains azacitidine, a hypomethylating antineoplastic agent used under haematology supervision in selected myelodysplastic syndromes, certain cases of acute myeloid leukaemia and chronic myelomonocytic leukaemia, according to local product information and guidelines.

Q2: Is Xpreza 100 mg given as an injection or a tablet?
Xpreza 100 mg is supplied as a vial of lyophilised powder that is reconstituted and given as a subcutaneous injection or intravenous dose, depending on protocol. It is not an oral tablet and should only be administered by trained healthcare professionals following the official instructions.

Q3: How long will I need to stay on azacitidine?
Many patients receive Xpreza 100 mg azacitidine injection for multiple cycles, often at least six or more, before treatment is fully evaluated. If there is clinical benefit and side effects remain manageable, therapy may continue for an extended period. The haematology team will review response, blood counts and quality of life regularly to decide how long to maintain azacitidine.

Q4: Can Xpreza 100 mg cure my MDS or AML?
Azacitidine is generally considered a disease-modifying treatment rather than a direct cure for most patients. It can improve blood counts, reduce transfusion needs, delay progression and extend survival in selected cases. In some patients it may be used as a bridge to transplantation, which offers the potential for long-term remission. Your team will explain realistic goals for your individual situation.

Q5: What monitoring is needed during treatment with Xpreza 100 mg?
Patients on Xpreza 100 mg azacitidine injection need regular full blood counts, kidney and liver function tests, clinical assessments for infection and bleeding, and review of injection sites and gastrointestinal symptoms. These checks help the team adjust doses, time cycles appropriately and provide supportive care to manage side effects safely.